ExploreWatchlistsPricing
  1. JP-listed companies
  3. Financials
  4. EBITDA

(4890)

Market cap
¥7.6B
P/E ratio
-10.4x
Tsubota Lab develops innovative treatments for eye conditions like myopia, dry eye, and presbyopia, plus brain diseases, using research from Keio University.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Mar 31, 2025264-143.05%
Mar 31, 2024-614-397.65%
Mar 31, 2023206+18.60%
Mar 31, 2022174-34.32%
Mar 31, 2021265+1372.65%
Mar 31, 202018

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat